Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 2/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079574 | 1.00 | TNKS (0.43) | TNKSTNKS2IDO1AVPR1AABCG2 | |
| SCHEMBL30954739 | 0.90 | TNKS (0.39) | TNKSTNKS2IDO1AVPR1AABCG2 | |
| SCHEMBL15144578 | 0.90 | TNKS (0.43) | TNKSTNKS2IDO1AVPR1AABCG2 | |
| SCHEMBL9057056 | 0.87 | TNKS (0.38) | TNKSTNKS2IDO1AVPR1AITGB2 | |
| SCHEMBL30954714 | 0.87 | TNKS (0.38) | TNKSTNKS2IDO1AVPR1AITGB2 | |
| SCHEMBL238700 | 0.86 | TNKS (0.41) | TNKSTNKS2IDO1AVPR1AABCG2 | |
| SCHEMBL655103 | 0.86 | TNKS (0.41) | TNKSTNKS2IDO1AVPR1A | |
| SCHEMBL30954744 | 0.85 | TNKS (0.46) | TNKSTNKS2IDO1AVPR1ASCD | |
| Hydrochloric Acid SCHEMBL2801131 | 0.85 | TNKS (0.41) | TNKSTNKS2IDO1AVPR1A | |
| SCHEMBL8359869 | 0.85 | TNKS (0.46) | TNKSTNKS2IDO1AVPR1ASCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934278-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| US-20190161479-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934278-B2 | Compounds | KCNA3, KCNN3, KCND3 | TNKS 4055/4885TNKS2 4022/4885IDO1 3582/4885 |
| US-20190161479-A1 | NOVEL COMPOUNDS | KCNN3, KCNA3, KCND3 | TNKS 3960/4885TNKS2 3691/4885IDO1 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.